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RESULTS 
This patient in acylcarnitines profile has a concentration of 3.7 M 
C5OH (N<0.52 M) and in profile of urinary organic acids only has 
excretion 3-hydroxyisovaleric acid without excretion of 3-
methylcrotonylglycine. 
The molecular study has allowed the identification in the MCCB gene 
of the frameshift mutation p.S173FfsX25 and the missense mutation 
p.V339M. Both mutations are described in the literature (3,4).  
The screening of 715.000 newborns lead to the identification of 31 
patients with high concentrations of C5OH (0.85 a 14.5 for normal 
until 0.57 M). 
The organic acid analysis in urine and in some cases molecular  studies 
allowed to establish a differential diagnosis in these patients (fig. 2). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-Distribution of patients according to differential diagnosis. 
 
DISCUSSION 
The 3-MCCD is a pathology not completely understood and its clinical 
phenotype is very heterogeneous, and often highly variable even 
within the same family. The phenotype ranges from neonatal onset 
with severe neurological involvement and even lethal cases to 
asymptomatic adults. Some patients develop an acute metabolic crisis 
usually triggered by intercurrent infections or introduction of a 
protein-rich diet in early childhood. A review of the literature on 37 
individuals indicates that only 27% developed normally and stayed 
completely asymptomatic. Approximately 30% were reported to suffer 
from muscular hypotonia and psychomotor retardation, respectively, 
and almost half suffer from various other neurological symptoms. 
Even a lethality of 11% was observed. (1) 
Most patients show private mutations in compound heterozygosity 
making the phenotype-genotype correlation difficult. 
The newborn screening identification of patients which can develop 
symptoms seems to indicate that this disease should be included in 
NBS programs. More studies are needed to find genetic and/or 
biochemical markers that explain why a relatively small number of 
individuals are at risk of developing a severe disease phenotype. 
This study demonstrated that an important reason to include 3-MCCD 
in our panel is that there are other disorders, some of which with 
severe phenotype, detected by the marker C5OH. If 3-MCCD was not 
part of the NBS panel, these patients would only be identified by the 
first symptoms, hindering the possibility to start early therapy and the 
aim of NBS is primarily to produce a good clinic outcome for babies by 
early diagnosis of treatable disorders, and facilitation of appropriate 
treatment. 
INTRODUCTION 
3-Methylcrotonylglycinuria (MCG) is an inborn error of the leucine 
catabolism resulting from isolated biotin-insensitive deficiency of 3-
methylcrotonyl-CoA carboxylase (3-MCCD), the enzyme converting 3-
methylcrotonoyl-CoA to 3-methylglutaconyl-CoA (1). 
Before the introduction of expanded newborn screening 3-MCCD was 
considered extremely rare but is now found in a number of 
asymptomatic babies or sometimes in their mothers. This is the 
commonest organic aciduria found by screening, with a incidence of 
about 1:32 392 in our country. 
The clinical phenotype has been shown to vary considerably, ranging 
from entirely asymptomatic to death in infancy. The metabolic 
phenotype characterizing 3-MCCD is the elevated excretion of the 
diagnostic compounds 3-methylcrotonylglycine and 3-
hydroxyisovaleric acid in the urinary organic acids , and the presence 
of abnormally elevated blood levels of 3-hydroxyisovalerylcarnitine 
(C5-OH), as determined by tandem mass spectrometry (MS/MS). 
Many patients also develop a severe secondary carnitine deficiency. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: The L-Leucine catabolic pathway and the site of the defect in 3-methylcrotonyl-CoA carboxylase 
deficiency (MCC). 
 
Increased C5OH, a side metabolic product of leucine and isoleucine 
metabolism (figure 1), can be associated to several diseases besides 
3-MCCD, namely 3-methylglutaconic hydratase deficiency, 2-methyl-
3-hydoxybutyryl-CoA dehydrogenase deficiency, 3-hydroxy-3-
methylglutaryl-CoA lyase deficiency (3-HMG), β-ketothiolase 
deficiency, holocarboxylase synthetase deficiency, and sometimes 
biotinidase deficiency. Only three of this diseases are included in the 
Portuguese Newborn Screening panel (3-MCCD, 3-HMG and 
holocarboxylase synthetase deficiency).  
The aim of this study is to demonstrate that although 3-MCCD has 
low clinical penetrance is important to identify these patients to 
prevent further decompensation. 
 
PATIENT AND METHODS 
The authors present a study case, a symptomatic 3-y-old-boy, of 
Spanish nationality, with an increase of C5-OH in the acylcarnitine 
profile who has a developmental delay. The genes MCCA and MCCB, 
encoding the 3-MCC enzyme were studied by standard methods. 
Since the beginning of extended Newborn Screening in 2004, about 
715.000 newborns samples collected between days 3 and 6 in 
Watman 903 filter paper blood spot, were tested through tandem 
mass spectrometry analysis of acylcarnitines as butyl esters (2).  
Suspected cases were confirmed through acylcarnitines analysis in a 
new blood spot sample and organic acid analysis in urine.  
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